Zacks Investment ResearchT3·17d ago
ALLR Allarity Therapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ALLR
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 8
- List Date
- 2021-12-21
- CIK
- 0001860657
- Next Earnings
- 2026-11-13
- EPS Forecast
- ($0.21) (1 est.)
- Headquarters
- Boston, MA
- Homepage
- https://www.allarity.com
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two g…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -22.91% | -3.47% | -19.98% | 0.90% | -12.28% | -11.55% |
| Feb | -- | -52.04% | -25.40% | -13.67% | -28.69% | 0.61% | -23.84% |
| Mar | -- | -47.01% | -73.33% | -26.74% | 6.45% | 9.55% | -26.22% |
| Apr | -- | -25.12% | -74.86% | -76.05% | 31.85% | 19.47% | -24.94% |
| May | -- | 88.67% | -33.29% | -55.04% | -25.94% | 26.15% | 0.11% |
| Jun | -- | -47.20% | -35.60% | -65.09% | 12.91% | -25.00% | -32.00% |
| Jul | -- | -7.69% | -59.68% | -19.68% | 0.00% | -8.33% | -19.08% |
| Aug | -- | -4.10% | -25.70% | 2.83% | 52.48% | 11.02% | 7.31% |
| Sep | -- | -2.58% | -54.17% | -58.01% | -1.25% | -26.06% | -28.41% |
| Oct | -- | -49.08% | -24.32% | -20.90% | -10.49% | -12.01%* | -23.36% |
| Nov | -- | -16.85% | 0.22% | -20.29% | -3.62% | -- | -10.13% |
| Dec | -1.20% | -36.13% | -6.61% | 8.33% | -13.60% | -- | -9.84% |
| Total | -1.20% | -96.59% | -99.80% | -99.55% | -5.22% | -27.64% | -55.00% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.93
SMA 50: $1.13
SMA 200: $1.22
Current: $0.92
EMA 12: $0.90
EMA 26: $0.97
MACD: -0.0714 | Signal: 0.0096
BEARISH
ADX (14): 28.02
TREND
+DI: 16.67
−DI: 24.26
Momentum Oscillators
RSI (14): 42.48
NEUTRAL
Stoch %K: 31.28
Stoch %D: 26.92
Williams %R: -52.04
Volume & Volatility
BB Upper: $1.07
BB Lower: $0.79
NEUTRAL
OBV: 467,555,042
Vol SMA 20: 124,264
Vol ROC: -58.16%
ATR: $0.08
True Range: $0.09
HV 20: 74.6%
HV 30: 74.4%
HV 60: 65.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: ALLR
Executive Summary
Confidence Level: 7/10 (BULLISH)
Key drivers: Recent positive news headlines, oversold RSI, bullish MACD signal, and improving volume trends.
Primary risks: High volatility, potential for a technical breakdown if price fails to break above the upper Bollinger Band.
Investment thesis: ALLR is poised for a short-term rebound as recent news sentiment and technical indicators align. However, high volatility remains a concern.
Recent news sentiment impact: Positive headlines have driven the stock higher, with a cumulative sentiment score of 4/5.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Uptrend; Medium-term (1-3 months): Sideways range; Long-term (3-12 months): Uptrend
Support/Resistance Levels:
- Upper Bollinger Band: $1.48
- Middle Bollinger Band: $1.39
- Lower Bollinger Band: $1.30
- SMA 20: $1.39
- SMA 50: $1.30
- EMA 12: $1.38
Momentum Signals:
- RSI (14): 38.14 (neutral)
- No immediate sell signal, but oversold conditions persist.
- MACD: Bullish signal above the signal line.
- Bollinger Bands: Oversold condition (price touching lower band).
Volume Analysis:
- Volume SMA 20: 88098.45
- On-Balance Volume (OBV): 447895639.14
- Volume Rate of Change: 617.99%
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines focus on clinical trial progress, patent allowance, and financing rounds.
Sentiment Assessment: Cumulative sentiment score: 4/5 (Positive)
Catalyst Identification: Upcoming presentations at ESMO Gynaecological Cancers Congress 2026 and potential FDA approval catalysts.
Market Narrative: Technical signals align with positive news sentiment, creating an uptrend.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock (beta >1.5) with a beta relative to SPY of 1.71.
Volatility Regime: High volatility regime persists, with current volatility levels above historical averages.
Options Market Signals:
- IV Premium vs HV30: N/A (positive = implied richer than realized)
Market Context & Positioning
Sector Performance: ALLR is outperforming the Healthcare sector by 2.5%.
Institutional Activity: Institutional interest is increasing, with a volume rate of change indicating buying pressure.
Correlation Analysis: ALLR has a moderate correlation (0.28) with the broader market (SPY).
Relative Valuation: ALLR is trading within its recent range, but with a slight upward bias.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $1.48
- Middle Bollinger Band: $1.39
- Lower Bollinger Band: $1.30
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band could trigger a significant move.
Time-Sensitive Catalysts: Upcoming presentations at ESMO Gynaecological Cancers Congress 2026 and potential FDA approval catalysts.
Risk Management: Monitor price action and adjust stop-loss levels accordingly. Consider reducing position size if volatility increases further.
Generated
News
All ALLR news →
GlobeNewswire Inc.T3·29d ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·13mo ago
Showing 1–10 of 50
Page 1 of 5
ALLR Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.4315
Alpha: -31.31%
Correlation: 0.2364
R-Squared: 5.6%
Stock Volatility: 77.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ALLR
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $428K | #2659 of 3138 | +45.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $118K | #5714 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ALLR Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ALLR Insider Trading (Form 4)
Latest: 2026-10-09Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Jeremy R. Graff | See Remarks | Mixed | +55,214 | $1.09 | -$35.2K | EDGAR |
| 2026-05-14 | Thomas Jensen | CEO | Award (A) | +200,000 | — | EDGAR | |
| 2026-05-11 | Jesper Hoeiland | Director | Award (A) | +25,000 | — | EDGAR | |
| 2026-05-07 | Gerald W. McLaughlin | Director | Award (A) | +45,000 | — | EDGAR | |
| 2026-01-16 | Jeremy R. Graff | See Remarks | Award (A) | +133,333 | — | EDGAR | |
| 2025-10-02 | Jeremy R. Graff | See Remarks | Mixed | +24,881 | $1.58 | -$23.1K | EDGAR |
| 2025-01-24 | Joseph Walter Vazzano | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-01-24 | Alexander Epshinsky | CFO | Award (A) | +29,496 | — | EDGAR | |
| 2025-01-24 | Joseph Walter Vazzano | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-01-24 | Laura Benjamin | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-01-24 | Laura Benjamin | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-01-24 | Gerald W. McLaughlin | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-01-24 | Gerald W. McLaughlin | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-01-24 | Thomas Jensen | CEO | Award (A) | +396,734 | — | EDGAR | |
| 2025-01-24 | Jeremy R. Graff | CDO | Award (A) | +144,441 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ALLR Insider Holdings
5 insiders · @ $0.92
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas Jensen | CEO | 596,734 | $546.1K | $0 | 2 | 2026-05-14 |
| 2 | Alexander Epshinsky | CFO | 85,051 | $77.8K | $0 | 1 | 2025-01-24 |
| 3 | Gerald W. McLaughlin | Director | 70,000 | $64.1K | $0 | 3 | 2026-05-07 |
| 4 | Jeremy R. Graff | See Remarks | 55,214 | $50.5K | $0 | 5 | 2026-10-09 |
| 5 | Jesper Hoeiland | Director | 25,000 | $22.9K | $0 | 1 | 2026-05-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ALLR Board & Officers
As of SEC filings through Oct 9, 2026Directors 2
- Gerald W. McLaughlin · since Oct 1, 2022
- Jesper Hoeiland · since Jun 10, 2025
Officers 3
- Thomas Jensen · CEO · listed since Jan 2025
- Jeremy R. Graff · President and Chief Development Officer · since Sep 30, 2024
- Jeffrey S Ervin · Chief Financial Officer · since Jul 1, 2025
Changes in the last 10 years (32)
| Jul 1, 2025 | Jeffrey S Ervin became Chief Financial Officer |
| Jun 30, 2025 | The company announced the departure of Alexander Epshinsky as Chief Financial Officer in an SEC filing |
| Jun 10, 2025 | Jesper Hoeiland became a director |
| Jun 5, 2025 | The company announced the departure of Joseph Walter Vazzano from the board in an SEC filing |
| Jan 24, 2025 | Thomas Jensen listed as CEO (previously SVP, Information Technology) in SEC filings |
| Sep 30, 2024 | Jeremy R. Graff became President and Chief Development Officer |
| Sep 12, 2024 | Alexander Epshinsky became Chief Financial Officer |
| Aug 1, 2023 | Laura Benjamin became a director |
| Aug 1, 2023 | Joseph Walter Vazzano became a director |
| Jul 21, 2023 | The company announced the departure of David Roth from the board in an SEC filing |
| Jan 19, 2023 | The company announced the departure of Soren Gade Jensen from the board in an SEC filing |
| Jan 19, 2023 | The company announced the departure of Gail J Maderis from the board in an SEC filing |
| Jan 19, 2023 | The company announced the departure of Duncan Moore from the board in an SEC filing |
| Oct 1, 2022 | Gerald W. McLaughlin became a director |
| Jul 7, 2022 | David Roth became a director |
| Jun 29, 2022 | Joan Yvonne Brown became Chief Financial Officer |
| Jun 27, 2022 | The company announced the departure of Steve Carchedi from the board in an SEC filing |
| Jun 27, 2022 | The company announced the departure of Steve Carchedi as Chief Executive Officer in an SEC filing |
| Jun 27, 2022 | Jens Erik Knudsen left as Chief Financial Officer, per their own SEC filing |
| Dec 20, 2021 | Thomas Jensen became SVP, Information Technology |
| Dec 20, 2021 | Steve Carchedi became a director |
| Dec 20, 2021 | Steve Carchedi became Chief Executive Officer |
| Dec 20, 2021 | Steen Knudsen became Chief Scientific Officer |
| Dec 20, 2021 | Soren Gade Jensen became a director |
| Dec 20, 2021 | Marie Foegh became Chief Medical Officer |
| Dec 20, 2021 | Leon Sass became a 10% owner |
| Dec 20, 2021 | Jens Erik Knudsen became Chief Financial Officer |
| Dec 20, 2021 | James G. Cullem became SVP, Chief Business Officer |
| Dec 20, 2021 | Gail J Maderis became a director |
| Dec 20, 2021 | Duncan Moore became a director |
| Dec 20, 2021 | Benny Sass became a 10% owner |
| Dec 20, 2021 | & Larsen ApS Sass became a 10% owner |
Not reported recently (8)
- Laura Benjamin · Last reported as a director in an SEC filing dated Jan 24, 2025
- Joan Yvonne Brown · Last reported as Chief Financial Officer in an SEC filing dated Jul 6, 2022
- Benny Sass · Last reported as a 10% owner in an SEC filing dated Dec 22, 2021
- Leon Sass · Last reported as a 10% owner in an SEC filing dated Dec 22, 2021
- & Larsen ApS Sass · Last reported as a 10% owner in an SEC filing dated Dec 22, 2021
- Steen Knudsen · Last reported as Chief Scientific Officer in an SEC filing dated Dec 22, 2021
- James G. Cullem · Last reported as SVP, Chief Business Officer in an SEC filing dated Dec 22, 2021
- Marie Foegh · Last reported as Chief Medical Officer in an SEC filing dated Dec 22, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold ALLR
1 shown · $180.38K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $180,385 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.